• DemeRx Receives MHRA Approval for DMX-1002 Study for Opioid Use Disorder americanpharmaceuticalreview
    March 17, 2021
    DemeRx IB, an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to ...
PharmaSources Customer Service